Source:http://linkedlifedata.com/resource/pubmed/id/22043355
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2011-11-1
|
| pubmed:abstractText |
Despite the scientific evidence of reducing cardiac events with HMG Co-A reductase inhibitors (statins) therapy in both primary and secondary preventions, these therapies continue to be underutilized in patients receiving convictional care. Simvastatin, a HMG Co-A inhibitor agent, is the most commonly used statin in Sultan Qaboos University Hospital. The aim of this study is to review the safety and the effectiveness of achieving LDL-C targets with Simvastatin according to the NCEP-ATP3 guidelines in patients with different cardiovascular risk categories at Sultan Qaboos University Hospital.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:status |
PubMed-not-MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
2070-5204
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
264-8
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Safety of simvastatin and goal attainment for low-density lipoprotein cholesterol in sultan qaboos university hospital.
|
| pubmed:publicationType |
Journal Article
|